Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194951 | 0.98 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP2C19ALOX5CCNA2 | |
| SCHEMBL7975173 | 0.93 | CYP2D6 (0.65) | CYP2D6CYP2C9CYP2C19ALOX5CCNA2 | |
| SCHEMBL8018069 | 0.84 | CYP2D6 (0.53) | CYP2D6CYP2C9CYP2C19SMN1; SMN2GAA | |
| SCHEMBL7972839 | 0.84 | CYP2D6 (0.53) | CYP2D6CYP2C9CYP2C19SMN1; SMN2GAA | |
| SCHEMBL7972123 | 0.84 | CYP2D6 (0.52) | CYP2D6SMN1; SMN2MAPTHTTHPGD | |
| SCHEMBL14590778 | 0.83 | HTT (0.65) | CYP2D6CYP2C9CYP2C19SMN1; SMN2GAA | |
| SCHEMBL7958989 | 0.82 | AURKA (0.48) | CYP2D6CYP2C9CCNA2CDK2CCNA1 | |
| SCHEMBL7968909 | 0.82 | CYP2D6 (0.50) | CYP2D6CYP2C9CYP2C19SMN1; SMN2GAA | |
| SCHEMBL14817973 | 0.81 | CYP2D6 (0.65) | CYP2D6GAAHTTALDH1A1HPGD | |
| SCHEMBL9191980 | 0.81 | CYP2D6 (0.75) | CYP2D6CYP2C9CYP2C19CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509120-A2 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | Amylyx Pharmaceuticals Inc. (US) | 2025-01-07 | — | — | US | claimed |
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | claimed |
| US-20210228488-A1 | EXTENDED RELEASE COMPOSITIONS AND PROCESS FOR PREPARATION | RUBICON RES PRIVATE LIMITED (IN) | 2021-07-29 | — | — | US | claimed |
| US-20190262268-A1 | ORAL MODIFIED RELEASE FORMULATIONS | RUBICON RES PRIVATE LIMITED (IN) | 2019-08-29 | — | — | US | claimed |
| WO-2018055641-A1 | ORAL MODIFIED RELEASE FORMULATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2018-03-29 | — | — | WO | claimed |
| US-20170128379-A1 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2017-05-11 | — | — | US | claimed |
| WO-2016001937-A2 | MODIFIED RELEASE PHARMACEUTICAL PREPARATIONS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2016-01-07 | — | — | WO | claimed |
| WO-2009005519-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-20060069104-A1 | Neurotrophic factor production accelerator | ASTELLAS PHARMA INC. (JP) | 2006-03-30 | — | — | US | claimed |
| EP-1498126-A1 | NEUROTROPHIC FACTOR PRODUCTION ACCELERATOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-19 | — | — | EP | claimed |
| US-20030045529-A1 | Method for specifically potentiating N-type Ca2+ channel activity | SHUJI KANEKO (JP) | 2003-03-06 | — | — | US | claimed |
| EP-0944612-B1 | N-(4-ACETYL-1-PIPERAZINYL)-4-FLUOROBENZAMIDE HYDRATE | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | claimed |
| US-6284760-B1 | ADMINISTERING A PIPERAZINO COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-04 | — | — | US | claimed |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | GLOBAL CANCER TECHNOLOGY INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-0944612-A1 | N-(4-ACETYL-1-PIPERAZINYL)-4-FLUOROBENZAMIDE HYDRATE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025914-A1 | N-(4-ACETYL-1-PIPERAZINYL)-4-FLUOROBENZAMIDE HYDRATE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998025914-A1 | N-(4-ACETYL-1-PIPERAZINYL)-4-FLUOROBENZAMIDE HYDRATE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ALOX5 969/4885CYP2D6 2637/4885CYP2C9 2152/4885 |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ALOX5 969/4885CYP2D6 2637/4885CYP2C9 2152/4885 |
| US-20030045529-A1 | Method for specifically potentiating N-type Ca2+ channel activity | CACNA1H, CACNA1B, CACNA1S | ALOX5 665/4885CYP2D6 1242/4885CYP2C9 1721/4885 |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | PIK3R4, PIK3R1, ATG7 | ALOX5 3936/4885CYP2D6 3359/4885CYP2C9 4053/4885 |
| US-20060069104-A1 | Neurotrophic factor production accelerator | BDNF, NTRK2, NGF | ALOX5 1097/4885CYP2D6 4015/4885CYP2C9 4317/4885 |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACHE, CHAT, BACE1 | ALOX5 145/4885CYP2D6 3153/4885CYP2C9 3328/4885 |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | HSPA9, CYP27A1, TUFM | ALOX5 969/4885CYP2D6 2637/4885CYP2C9 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.